Venous thromboembolism in young female while on oral contraceptives: High frequency of inherited thrombophilia and analysis of thrombotic events in 400 Czech women

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 5, 2009, Pages 567-573

  Dulíček, Petr ^a   Malý, Jaroslav ^a   Pecka, Miroslav ^a   Beránek, Martin ^a   Čermáková, Eva ^a   Malý, Radovan ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Acquired thrombophilia; Inherited thrombophilia; Oral contraceptive use; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CZECH REPUBLIC; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; HUMAN; IMMOBILIZATION; INJURY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAJOR SURGERY; MINOR SURGERY; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL; CZECH REPUBLIC; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 70449638769     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608325544     Document Type: Article

References (29)

1. NordstrOüm M., Lindblad B., Bergqvist D., KjellstrOüm T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992 ; 232: 155-160.
2. Vandenbroucke JP, Koster T., Brit E., Reitsma PH, Bertina RM, Rosendaal FR Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994 ; 344: 1453-1457.
3. Blickstein D., Blickstein I. Oral contraception and thrombophilia. Curr Opin Obstet Gyencol. 2007 ; 19: 370-376.
4. Wu O., Robertson L., Langhorne P., et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005 ; 94: 17-25.
5. HrachovinovÁ Z., VorlovÁ Z. Simultaneous presence of prothrombin 20210A and factor F Leiden does not increase risk of venous thromboembolism. Blood. 1998 ; 92 (suppl 1). 120 b.
6. Dulíek P., Malý J., SafÁÅ™ovÁ M. Risk of thrombosis in patients homozygous and heterozygous for factor V Leiden in the East Bohemian region. Clin Appl Thromb Hemost. 2000 ; 6: 87-90.
7. Dulíek P., Malý J., PeÅavovÁ L., Pecka M. Prevalence of inherited thrombophilia in young thrombosis patients from the East Bohemian region. Blood Coagul Fibrinolysis. 2002 ; 13: 569-573.
8. World Health Organisation. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995 ; 346: 1575-1582.
9. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000 ; 160: 49-52.
10. Herings RMC, Urquhart J., Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999 ; 354: 127-128.
11. Kemmeren JM, Algra A., Grobbee DE Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001 ; 323: 131-134.
12. Battaglioni T., Martinelli I. Hormone therapy and thromboembolic disease. Curr Opin Hematol. 2007 ; 14: 488-489.
13. World Health Organization. Cardiovascular Disease and Steroid Hormone Contraception. Report of a WHO Scientific Group. WHO Technical Report Series 877. Geneva: World Health Organization ; 1998.
14. Abdollahi M., Cushman M., Rosendaal FR Obesity: risk factors and oral contraceptive use. Thromb Haemost. 2003 ; 89: 493-498.
15. Martinelli I., Taioli E., Battaglioli T., et al. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. Arch Intern Med. 2003 ; 163: 2771-2774.
16. Legnani C., Palareti G., Guazzaloca G., et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J. 2002 ; 23: 984-990.
17. Schambeck CM, Schwender S., Haubitz I., Geisen UE, Grossmann RE, Keller F. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives ? Thromb Haemost. 1997 ; 78: 1480-1483.
18. Martinelli I., Taioli E., Bucciarelli P., Akhavan S., Mannucci PM Interaction between the G20210A mutation of the prothrombin gene ad oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol. 1999 ; 19: 700-703.
19. Cosmi B., Legnani C., Bernardi F., Cocheri S., Palareti G. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med. 2003 ; 163: 1105-1109.
20. Emmerich J., Rosendaal FR, Cattaneo M., et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001 ; 86: 809-816.
21. Santamaria A., Mateo J., Oliver A., et al. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of G20210A mutation of the prothrombin gene. Haematologica. 2001 ; 86: 965-971.
22. Pabinger I., Scheider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost. 1994 ; 71: 548-552.
23. Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J. 1996 ; 131: 1145-1148.
24. Legnani C., Cosmi B., Valdre L., et al. Venous tromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost. 2003 ; 1: 112-117.
25. Kujovich JK Hormones and pregnancy: thromboembolic risks for women. Br J Haematol. 2004 ; 126: 443-454.
26. Tans G., Curvers J., Middeldorp S., et al. A randomised a cross over study on the effects of levonorgestrel and desogestrel containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000 ; 84: 15-21.
27. Middeldorp S., Meijers JCM, van den Ende AE, et al. Effects on coagulation of levonorgestrel and desogestrel containing low dose oral contraceptives: a cross over study. Thromb Haemost. 2000 ; 84: 4-8.
28. Chan HH, Douketis JD, Nowaczyk MJ Acute renal vein thrombosis, oral contraceptive use, and hyperhomocysteinemia. Mayo Clin Proc. 2001 ; 76: 212-214.
29. Dentali F., Crowther M., Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood. 2006 ; 107: 2766-2773.